• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

低分化及未分化甲状腺癌。

Poorly differentiated and anaplastic thyroid cancer.

作者信息

Patel Kepal N, Shaha Ashok R

机构信息

Department of Surgery, Stony Brook University Hospital, Stony Brook, New York, USA.

出版信息

Cancer Control. 2006 Apr;13(2):119-28. doi: 10.1177/107327480601300206.

DOI:10.1177/107327480601300206
PMID:16735986
Abstract

BACKGROUND

Poorly differentiated thyroid carcinoma (PDTC) and anaplastic (undifferentiated) thyroid carcinoma (ATC) comprise a small subset of thyroid tumors that are associated with a poor prognosis and account for a significant portion of the morbidity and mortality related to thyroid cancer. Since management strategies vary between these two entities, it is important for clinicians to be able to differentiate PDTC from ATC.

METHODS

We reviewed the literature on PDTC and ATC and compared clinical and histopathologic features important in defining the disease process.

RESULTS

Both PDTC and ATC display aggressive behavior with increased locoregional and distant disease. In most cases, patients are older and have large, locally advanced tumors. PDTC may represent an intermediate entity in the progression of well-differentiated thyroid carcinoma to ATC. The use of surgical management may be curative or palliative and differs between PDTC and ATC. The roles of radiotherapy and chemotherapy have not been well described.

CONCLUSIONS

PDTC and ATC are rare diseases that carry a poor prognosis. Recognition of their different clinicopathologic features is important to the optimal management of these tumors.

摘要

背景

低分化甲状腺癌(PDTC)和间变性(未分化)甲状腺癌(ATC)是甲状腺肿瘤中的一小部分,预后较差,在甲状腺癌相关的发病率和死亡率中占很大比例。由于这两种实体的治疗策略不同,临床医生能够区分PDTC和ATC很重要。

方法

我们回顾了关于PDTC和ATC的文献,并比较了在定义疾病过程中重要的临床和组织病理学特征。

结果

PDTC和ATC均表现出侵袭性,局部和远处疾病增加。在大多数情况下,患者年龄较大,患有大的局部晚期肿瘤。PDTC可能代表分化良好的甲状腺癌向ATC进展过程中的一个中间实体。手术治疗的使用可能是治愈性的或姑息性的,PDTC和ATC之间有所不同。放疗和化疗的作用尚未得到充分描述。

结论

PDTC和ATC是罕见疾病,预后较差。认识到它们不同的临床病理特征对于这些肿瘤的最佳管理很重要。

相似文献

1
Poorly differentiated and anaplastic thyroid cancer.低分化及未分化甲状腺癌。
Cancer Control. 2006 Apr;13(2):119-28. doi: 10.1177/107327480601300206.
2
Changes of Clinicopathologic Characteristics and Survival Outcomes of Anaplastic and Poorly Differentiated Thyroid Carcinoma.间变性和低分化甲状腺癌的临床病理特征变化及生存结局。
Thyroid. 2016 Mar;26(3):404-13. doi: 10.1089/thy.2015.0316. Epub 2015 Dec 14.
3
Recurrence and Survival After Gross Total Removal of Resectable Undifferentiated or Poorly Differentiated Thyroid Carcinoma.可切除的未分化或低分化甲状腺癌全切除术后的复发与生存情况
Thyroid. 2016 Sep;26(9):1259-68. doi: 10.1089/thy.2016.0147. Epub 2016 Aug 11.
4
Anaplastic and poorly differentiated thyroid carcinoma: therapeutic strategies and treatment outcome of 52 consecutive patients.间变性和低分化甲状腺癌:52 例连续患者的治疗策略和治疗结果。
Oncology. 2010;79(5-6):400-8. doi: 10.1159/000322640. Epub 2011 Mar 31.
5
Anaplastic thyroid cancer: prevalence, diagnosis and treatment.间变性甲状腺癌:患病率、诊断与治疗
Minerva Endocrinol. 2008 Dec;33(4):341-57.
6
Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing.采用靶向二代测序技术对低分化和间变性甲状腺癌进行突变分析。
Histopathology. 2019 Dec;75(6):890-899. doi: 10.1111/his.13942. Epub 2019 Oct 13.
7
Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.由 STRN-ALK 表达和 p53 缺失驱动的甲状腺癌进展和去分化的小鼠模型:两种低分化癌存在的证据。
Thyroid. 2019 Oct;29(10):1425-1437. doi: 10.1089/thy.2019.0284. Epub 2019 Aug 16.
8
Poorly Differentiated and Undifferentiated Thyroid Carcinomas.低分化及未分化甲状腺癌
Turk Patoloji Derg. 2015;31 Suppl 1:48-59. doi: 10.5146/tjpath.2015.01314.
9
Predictive value of hematologic parameters and clinicopathological features of poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma.血液学参数及低分化甲状腺癌和间变性甲状腺癌临床病理特征的预测价值。
Langenbecks Arch Surg. 2024 Aug 6;409(1):241. doi: 10.1007/s00423-024-03431-8.
10
Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma.对失调的微小RNA进行分析有助于鉴别低分化甲状腺癌和乳头状甲状腺癌。
Horm Metab Res. 2009 Jun;41(6):475-81. doi: 10.1055/s-0029-1215593. Epub 2009 Apr 15.

引用本文的文献

1
Long-Term Effect of TIMP3 Gene Expression on Thyroid Cancer: A Cure Model Analysis.TIMP3 基因表达对甲状腺癌的长期影响:治愈模型分析。
Asian Pac J Cancer Prev. 2024 Oct 1;25(10):3627-3634. doi: 10.31557/APJCP.2024.25.10.3627.
2
Exploring the potential of myo-inositol in thyroid disease management: focus on thyroid cancer diagnosis and therapy.探讨肌醇在甲状腺疾病管理中的潜力:聚焦甲状腺癌的诊断与治疗。
Front Endocrinol (Lausanne). 2024 Sep 12;15:1418956. doi: 10.3389/fendo.2024.1418956. eCollection 2024.
3
Prognosis of Poorly Differentiated Thyroid Carcinoma: A Systematic Review and Meta-Analysis.
低分化甲状腺癌的预后:系统评价和荟萃分析。
Endocrinol Metab (Seoul). 2024 Aug;39(4):590-602. doi: 10.3803/EnM.2024.1927. Epub 2024 Jun 27.
4
BUB1/KIF14 complex promotes anaplastic thyroid carcinoma progression by inducing chromosome instability.BUB1/KIF14 复合物通过诱导染色体不稳定性促进间变性甲状腺癌的进展。
J Cell Mol Med. 2024 Apr;28(7):e18182. doi: 10.1111/jcmm.18182.
5
Leveraging molecular targeted drugs and immune checkpoint inhibitors treat advanced thyroid carcinoma to achieve thyroid carcinoma redifferentiation.利用分子靶向药物和免疫检查点抑制剂治疗晚期甲状腺癌以实现甲状腺癌再分化。
Am J Cancer Res. 2024 Feb 15;14(2):407-428. doi: 10.62347/EJAA3388. eCollection 2024.
6
Knowledge mapping of anaplastic thyroid cancer treatments: a bibliometric analysis (2000-2023).间变性甲状腺癌治疗的知识图谱:一项文献计量分析(2000 - 2023年)
Front Oncol. 2024 Feb 14;14:1330030. doi: 10.3389/fonc.2024.1330030. eCollection 2024.
7
Poorly differentiated thyroid carcinomas: conceptual controversy and clinical impact.未分化甲状腺癌:概念争议与临床影响。
Virchows Arch. 2024 May;484(5):733-742. doi: 10.1007/s00428-024-03752-5. Epub 2024 Feb 24.
8
Nano-approaches and Recent Advancements in Strategies to Combat Challenges Associated with Thyroid Cancer Therapies.应对甲状腺癌治疗相关挑战的纳米方法及策略的最新进展
Recent Pat Nanotechnol. 2025;19(3):381-394. doi: 10.2174/0118722105257210230929083126.
9
Ga-68 Prostate-Specific Membrane Antigen-HBED-CC Positron Emission Tomography/Computed Tomography in Anaplastic Thyroid Carcinoma.镓-68前列腺特异性膜抗原-HBED-CC正电子发射断层扫描/计算机断层扫描在间变性甲状腺癌中的应用
Indian J Nucl Med. 2022 Oct-Dec;37(4):310-317. doi: 10.4103/ijnm.ijnm_21_22. Epub 2022 Dec 2.
10
Case report: Visibly curative effect of dabrafenib and trametinib on advanced thyroid carcinoma in 2 patients.病例报告:达拉非尼和曲美替尼对2例晚期甲状腺癌患者的显著疗效。
Front Oncol. 2023 Jan 5;12:1099268. doi: 10.3389/fonc.2022.1099268. eCollection 2022.